Document:

EX-10.33  TERMINATION OF LOAN DOCUMENTS

 

Exhibit 10.33

TERMINATION OF LOAN DOCUMENTS

AND INVESTORS’ RIGHTS AGREEMENT

(Sirion Therapeutics, Inc. and PharmaBio Development Inc.)

     This
Termination Agreement (this
“Agreement”) dated as of September 13, 2006, is made
and entered into by and among Sirion Therapeutics, Inc., a North Carolina corporation
(“Borrower”), PharmaBio Development Inc. (d/b/a NovaQuest), a North Carolina corporation
(“Lender”), and the individuals listed as “Shareholders” on Exhibit A (the “Founders”) to
the Investors’ Rights Agreement (as defined below). Capitalized terms used but not defined herein
shall have the meanings given to them in the Loan Agreement (as defined below).

Recitals

     Whereas, Borrower and Lender are parties to the following agreements and instruments
executed in connection with a $5,000,000 convertible loan (the “Loan”) made by Lender to Borrower
pursuant to the terms thereof:

	 	 	 	 	 
	 

	 	“Loan Agreement”
	 	Collectively, that certain Loan Agreement, dated
February 14, 2006, and that certain First Amendment
to Loan Agreement dated July 5, 2006, with Borrower
as borrower and Lender as lender; and
	 
	 	 	 	 
	 

	 	“Promissory Note”
	 	That certain Promissory Note, dated February 14,
2006, in the principal amount of $5,000,000, issued
by Borrower to Lender; and
	 
	 	 	 	 
	 

	 	“Security Agreement”
	 	That certain Security Agreement, date February 14,
2006, with Borrower as grantor and Lender as secured
party;

the Loan Agreement, Promissory Note and Security Agreement being collectively referred to as the
“Loan Documents”; and

     Whereas, in connection with the Loan, Lender, Borrower and the Founders also entered
into that certain Investor Rights Agreement, dated February 14, 2006 (the “Investors’ Rights
Agreement”); and

     Whereas, Borrower and Borrower’s shareholders are preparing to enter into a
contribution transaction (the “Contribution”) pursuant to which all the holders of shares of
capital stock in Borrower (the “Sirion Shareholders”) will contribute all of their capital stock in
Borrower to Tenby Pharma, Inc., a “public shell” corporation incorporated in Delaware (“Tenby” ),
in return for capital stock of Tenby, pursuant to a Contribution Agreement by and among all the
Sirion Shareholders, Borrower and Tenby (the “Contribution Agreement”); and

 

 

     Whereas, the Contribution qualifies as the “Second Merger” under the Loan Agreement;
and

     Whereas, Lender has advanced to Borrower the full $5,000,000 in Advances available
under the Loan Agreement and Note; and

     Whereas, pursuant to the terms of the Loan Agreement, immediately before the closing
of the Contribution, all outstanding Advances and any accrued but unpaid interest amount thereon
will be automatically converted into 100,000 shares of Borrower’s Series A-1 Preferred Stock; and

     Whereas, pursuant to Section 5.2 of the Contribution Agreement, it is a condition to
the Closing (as defined in the Contribution Agreement) that the parties to the Loan Documents
terminate such Loan Documents.

     Now Therefore, in consideration of the premises set forth above, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties agree as follows:

Agreement

     1. Termination. Effective as of, and contingent upon the occurrence of, the
Closing (as defined in the Contribution Agreement), Lender and Borrower agree that the Loan
Documents shall be terminated in their entirety, and Lender, Borrower and the Founders agree that
the Investors’ Rights Agreement shall be terminated in its entirety; provided,
however, that the parties agree that, in the event that the Closing fails to occur, this
Agreement shall be null and void and the parties shall retain all of the rights and obligations of
such parties pursuant to the Loan Documents and the Investors’ Rights Agreement, as the case may
be, which shall remain in full force and effect.

     2. Entire Agreement. This Agreement contains the full and entire
understanding among the parties hereto with respect to the subjects hereof.

     3. Counterparts. This Agreement may be executed in two or more
counterparts, and may be delivered by facsimile or other electronic delivery, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument.

     4. Governing Law. This Agreement, and the rights and obligations of the
parties arising hereunder or in connection herewith, shall be governed by and construed in
accordance with the Laws of the State of North Carolina, as applied to agreements executed and
performed entirely in the State of North Carolina, without regard to its conflicts of law rules.

[REMAINDER OF PAGE LEFT INTENTIONALLY BLANK.]

2

 

     In Witness Whereof, the parties have executed this Termination of Loan Documents
and Investors’ Rights Agreement as of the date first written above.

	 	 	 	 	 
	 	 	SIRION THERAPUETICS, INC.
	 
	 	 	 	 
	 

	 	By:	 	/s/ Barry Butler 
	 

	 	 	 	 
	 

	 	 	 	Barry Butler, President and
	 

	 	 	 	     Chief Executive Officer
	 
	 	 	 	 
	 	 	PHARMABIO DEVELOPMENT INC.
	 	 	(d/b/a NOVAQUEST)
	 
	 	 	 	 
	 

	 	By:	 	/s/ Kerry E. Zook 
	 

	 	 	 	 
	 

	 	 	 	Kerry E. Zook, Vice President
	 
	 	 	 	 
	 	 	FOUNDERS:
	 
	 	/s/ Susan Benton 
	 	 	 
	 	 	Susan Benton
	 
	 	/s/ Phillipe Boulangeat 
	 	 	 
	 	 	Phillipe Boulangeat
	 
	 	/s/ Barry Butler 
	 	 	 
	 	 	Barry Butler
	 
	 	/s/ Roger Vogel 
	 	 	 
	 	 	Roger Vogel, M.D.EX-10.34  MASTER LABORATORY SERVICES AGREEMENT

 

Exhibit 10.34

MASTER LABORATORY SERVICES AGREEMENT

     This Master Laboratory Services Agreement (“Agreement”), when signed by both parties, will set
forth the terms and conditions between Rx DEVELOPMENT RESOURCES, a Florida corporation with its
principal offices located at 3104 Cherry Palm Drive, Suite 260, Tampa, Florida 33619 (“Sponsor”)
and QUINTILES LABORATORIES LIMITED, a North Carolina corporation with its principal offices located
at 5500 Highlands Parkway, Suite 600, Smyrna, Georgia 30082 (“QLAB”), under which QLAB agrees to
provide laboratory services to Sponsor as set forth below.

Sponsor and QLAB agree as follows:

1. Services. QLAB shall provide study planning, consultation on laboratory design, laboratory
analysis, other laboratory services, and/or data management services, as requested by Sponsor from
time to time during the term of this Agreement. The specific details of each assignment or task
will be separately negotiated and specified in writing on terms acceptable to the parties and
otherwise subject to the terms and conditions of this Agreement (each such writing, a Confirmation
of Central Laboratory Services (“CCLS”)) in a document substantially in the form of Appendix
I to this Agreement.

2. Payment of Fees and Expenses.

     (a) Each CCLS shall contain a Line Item Budget (“Budget”) for the payment of QLAB’s services
to be performed pursuant to such CCLS as well as additional terms and conditions related to the
Budget. Sponsor will pay QLAB in accordance with each Budget. Sponsor shall reimburse QLAB for all
reasonable and necessary travel, lodging and other expenses incurred in the performance of its
services that have been requested or approved by Sponsor.

     (b) At the point Sponsor asks QLAB to begin work on an individual project, Sponsor shall pay
QLAB an amount equal to ten percent (10%) of the applicable Budget as a project initiation payment,
which project initiation payment shall be credited back to Sponsor on the final invoice. QLAB will
draw from these funds in order to pay for services and related costs and expenses consistent with
the terms of this Agreement.

     (c) QLAB will invoice Sponsor monthly or as separately agreed for services rendered under any
CCLS and Sponsor shall pay all amounts due within thirty (30) days of receipt of QLAB’s itemized
invoices for work completed. Each invoice will reflect QLAB’s application of any amounts advanced
by Sponsor. If any portion of an invoice is disputed, then Sponsor shall pay the undisputed amounts
within 30 days of receipt of the invoice, and the parties shall use good faith efforts to reconcile
the disputed amounts as soon as practicable. Sponsor shall pay QLAB interest in an amount equal to
one percent (1%) per month (or the maximum lesser amount permitted by law) of all undisputed
amounts owing hereunder and not paid within thirty (30) days of the date of the invoice.

- 1 -

 

3. Term. This Agreement shall commence on the date of execution and shall continue for
five years from the date of execution or until terminated as hereinafter provided by either
party.

4. Confidentiality.

     (a) It
is understood that during the term of this Agreement and each CCLS, QLAB and its
employees may be exposed to data and information that is confidential and proprietary to Sponsor.
All such data and information (“Sponsor Confidential Information”) made available, disclosed or
otherwise made known to QLAB as a result of services under this Agreement or under any CCLS shall
be considered confidential and shall be considered the sole property of Sponsor. All
information regarding laboratory methods, laboratory pricing, and laboratory management and all
information regarding QLAB’s operations, including but not limited to QLAB Property (as defined
in Section 5 below), disclosed by QLAB to Sponsor in connection with this Agreement or any CCLS
is proprietary, confidential information belonging to QLAB (the “QLAB Confidential Information”,
and together with the Sponsor Information, the “Confidential Information”). The Confidential
Information shall be used by the receiving party and its employees only for purposes of
performing the receiving party’s obligations hereunder or under any CCLS. Each party agrees that
it will not reveal, publish or otherwise disclose the Confidential Information of the other party
to any third party without the prior written consent of the disclosing party.

     (b) The foregoing obligations shall not apply to Confidential Information which:

	 	(i)	 	is or becomes generally available to the public other
than as a result of a disclosure by the receiving party;
	 
	 	(ii)	 	becomes available to the receiving party on a
non-confidential basis from a source which is not prohibited from disclosing
such information by a legal, contractual or fiduciary obligation to the
disclosing party;
	 
	 	(iii)	 	the receiving party develops independently of
any disclosure by the disclosing party;
	 
	 	(iv)	 	was in the receiving party’s possession or known to the receiving party prior to its
receipt from the disclosing party, as shown by contemporaneous written evidence; or
	 
	 	(v)	 	is required by law to be disclosed.

     (c) This obligation of confidentiality and non-disclosure shall remain in effect for a
period of ten years after the termination of this Agreement.

- 2 -

 

5. Property Ownership.

     (a) All data and information necessary for QLAB to conduct project assignments will be
forwarded by Sponsor to QLAB, and all such information received from Sponsor shall remain the
property of Sponsor.

     (b) All data and information generated or derived by QLAB as the result of services
performed by QLAB under this Agreement shall be and remain the exclusive property of Sponsor. Any
inventions that may evolve from the data and information described above or as the result of
services performed by QLAB under this Agreement shall belong to Sponsor, and QLAB agrees to
assign its rights in any inventions and/or related patents to Sponsor.

     (c) Notwithstanding the foregoing, Sponsor acknowledges that QLAB possesses certain
inventions, processes, know-how, trade secrets, improvements, other intellectual properties and
other assets, including but not limited to laboratory analyses, analytical and laboratory
methods, processes, approaches, procedures and techniques, technical expertise and conceptual
expertise in area of laboratory services, procedure manuals, personnel data, financial
information, computer technical expertise, and software, which have been independently developed
by QLAB and which relate to its business or operations (collectively “QLAB Property”). Sponsor
and QLAB agree that any QLAB Property or improvements thereto which are used, improved, modified
or developed by QLAB under or during the term of this Agreement or any CCLS are the sole and
exclusive property of QLAB.

     (d) At the completion of the services by QLAB, all materials and other data owned by Sponsor
shall either be: (i) delivered to Sponsor in such form as is then currently in the possession of
QLAB, subject to the payment obligations set forth in Section 2 herein; (ii) retained by QLAB for
Sponsor for a period of two (2) years; or, (iii) disposed of, at the direction and written
request of Sponsor. Sponsor shall pay the costs associated with any of the above options. QLAB,
however, reserves the right to retain, at its own cost and subject to the confidentiality
provisions herein, one copy of all documents and materials relating to the services, to be used
solely to satisfy regulatory requirements or to resolve disputes regarding the services.

6. Regulatory Compliance; Inspections.

     (a) In carrying out its responsibilities under this Agreement and each CCLS, QLAB agrees to
conduct its services in substantial compliance with all applicable laws, rules and regulations,
including but not limited to the U.S. Food, Drug and Cosmetic Act and the regulations
promulgated pursuant thereto, ICH GCP Guideline UK SI 2004; 1031 Part 2 where applicable and
with the standard of care customary in the central laboratory industry. Regarding the FDA’s
electronic records and signatures regulation, 21 CFR Part 11 (“Part 11”), QLAB has a compliance
plan in place as to its applicable database applications and electronic records systems and it
is working diligently to implement its plan. QLAB, however, is not responsible for the
compliance or non-compliance of applications or systems used by third parties (including, but
not limited to, investigative sites or third party laboratories) or for any Part 11 audits or
assessments thereof, unless such applications or systems are owned by QLAB. QLAB’s standard
operating procedures will be used in performance of the Services, unless otherwise specifically
stated in the CCLS.

- 3 -

 

     (b) Sponsor warrants that neither any assignment or task requested by Sponsor nor the conduct
thereof as provided in this Agreement or in any CCLS shall violate any applicable law or
regulation. Sponsor shall notify QLAB promptly in writing of any FDA or other governmental
inspection or inquiry concerning any services that have been rendered or are being rendered by
QLAB, or any study or project to which such services relate.

     (c) Neither QLAB nor any of QLAB’s employees rendering services pursuant to this Agreement has
been debarred pursuant to the Generic Drug Enforcement Act of 1992 and QLAB will not knowingly
employ any person or entity that has been so debarred to perform services under this Agreement or
any CCLS. QLAB shall notify Sponsor immediately upon the commencement of any such proceeding
concerning QLAB or any such employee.

     (d) If any governmental or regulatory authority conducts or gives notice to QLAB of its intent
to conduct an inspection at QLAB’s facilities or take any other regulatory action with respect to
any study or services provided under this Agreement, QLAB will promptly give Sponsor notice
thereof, including all information pertinent thereto, and, where reasonably practicable, QLAB will
notify Sponsor prior to complying with such a demand or request. Sponsor, however,
acknowledges that it may not direct the manner in which QLAB fulfills its obligations to permit
inspection by governmental entities.

     (e) During the term of this Agreement and each CCLS, QLAB will permit Sponsor’s
representative(s) (unless such representatives are competitors of QLAB) to examine the work
performed hereunder and the specific facilities at which the work is conducted during regular
business hours upon reasonable advance notice and in a reasonable manner to determine that the
project assignment is being conducted in accordance with the applicable CCLS and that the
facilities are adequate; provided, however, that all information disclosed or revealed to or
ascertained by Sponsor in connection with any such examination shall be deemed to constitute QLAB
Confidential Information for purposes of this Agreement. Unless the costs of governmental or
Sponsor audits are specifically included in the Budget, Sponsor shall reimburse QLAB for its time
and expenses associated with such audits and investigations.

7. Conflict of Agreements. QLAB represents to Sponsor that QLAB is not a party to any agreement
which would prevent QLAB from fulfilling its obligations under this Agreement, and that during the
term of this Agreement, QLAB will not enter into an agreement to provide services which would
prevent QLAB from providing the services contemplated to be provided by QLAB under this Agreement
or any CCLS.

- 4 -

 

8. Indemnification.

     (a) Sponsor shall defend, indemnify and hold harmless QLAB, its affiliates and its and their
respective directors, officers, employees and agents (each, an “Indemnified Party”) from and
against any and all losses, claims, actions, damages, liabilities, costs and expenses, (including
reasonable attorney’s fees and court costs) (collectively, “Losses”), joint or several, resulting
or arising from any third-party claims, actions, proceedings, investigations or litigation relating
to or arising from or in connection with this Agreement or any CCLS or the services contemplated
herein (including, without limitation, any Losses arising from or in connection with any study,
test, product or potential product to which this Agreement or any CCLS relates), except to the
extent such Losses are determined to have resulted solely from negligence or intentional misconduct
of the Indemnified Party seeking indemnity hereunder.

     (b) QLAB shall: (i) give Sponsor prompt notice of any such claim or law suit (including a copy
thereof served upon QLAB); (ii) cooperate with Sponsor and its legal representatives in the
investigation of any matter the subject of indemnification, and (iii) not unreasonably withhold its
approval of the settlement of any such claim, liability or action by Sponsor that is the subject of
this Indemnification provision.

9. Limitation of Liability. Neither QLAB nor its affiliates nor any of its or their respective
directors, officers, employees, subcontractors or agents shall have any liability of any type
(including, but not limited to, contract, negligence and tort liability) for any loss of profits,
opportunity or goodwill, or any type of special, incidental, indirect or consequential damage or
loss in connection with or arising out of this Agreement, any CCLS, or the Services performed by
QLAB hereunder, even if such damages may have been foreseeable to QLAB. In addition, in no event
shall the collective, aggregate liability of QLAB and its affiliates and its and their respective
directors, officers, employees and agents under this Agreement or any CCLS exceed the amount of
fees actually received by QLAB from Sponsor pursuant to this Agreement for the assignment or task
from which such liability arose.

10. Disclosure of Hazards. Sponsor shall provide QLAB with all information available to it
regarding known or potential hazards associated with the use of any substances supplied to QLAB by
Sponsor and Sponsor shall comply with all current legislation and regulations concerning the
shipment of substances by land, sea or air.

11. Publication. Project results may not be published or referred to, in whole or in part, without
the prior written consent of Sponsor. Neither party may use the other party’s name in connection
with any publication or promotion without the other party’s prior, written consent.

12. Termination.

     (a) This Agreement or any CCLS may be terminated with or without cause by Sponsor or by QLAB
at any time during the term of this Agreement on ninety (90) days prior written notice to QLAB or
Sponsor, as appropriate.

- 5 -

 

     (b) Either party may terminate this Agreement or any CCLS for material breach upon
thirty (30) days written notice specifying the nature of the breach, if such breach has not been
substantially cured within the thirty (30) day period. In the event that QLAB determines, in its
sole discretion, that its continued performance of the services contemplated by a CCLS would
constitute a potential or actual violation of regulatory or scientific standards of integrity, QLAB
may terminate this Agreement or the applicable CCLS by giving written notice stating the effective
date (which may be less than thirty days from the notice date) of such termination.

     (c) Termination of this Agreement shall constitute termination of all CCLS’s hereunder.
Termination of a CCLS shall constitute a termination of such CCLS only and shall not affect this
Agreement or any other CCLS’s outstanding hereunder. Any written termination notice shall
identify each specific CCLS that is being terminated.

     (d) In the event this Agreement is terminated, Sponsor shall pay to QLAB: (i) any fees for
services rendered then due and owing to QLAB because of any performance of QLAB’s obligations
hereunder and all expenses reasonably incurred in performing those services; (ii) all actual costs
(including time spent by QLAB personnel, which shall be billed at QLAB standard rates) to complete
activities associated with the termination and close out of projects; and (iii) all kit destruction
costs as noted in each CCLS. If payments in a terminated CCLS are milestone-based, but that
milestone has not yet been completed, Sponsor will pay QLAB’s standard fees for actual work
performed toward that milestone up to the date of termination. Upon the termination of this
Agreement, QLAB shall deliver to Sponsor all data and materials provided by Sponsor to QLAB for the
conduct of services under this Agreement.

     (e) Termination of this Agreement or any CCLS hereunder shall not constitute a release or
waiver of any right or remedy available to either party in connection herewith or therewith.

13. Independent Contractor Relationship. Notwithstanding any provision herein to the contrary,
the parties hereto are independent contractors, and nothing contained in this Agreement or in any
CCLS shall be construed to place them in the relationship of partners, principal and agent,
employer and employee, or joint venturers. Each party agrees that it shall have no power or right
to bind or obligate the other, and neither party shall hold itself out as having such authority.

14. Insurance. During the term of this Agreement to cover its obligations hereunder, each party
shall maintain insurance coverage as follows: 1) (a) Professional Liability for QLAB in an amount
of at least US$10,000,000.00; (b) Product Liability for Sponsor in an amount of at least
US$10,000,000.00; and 2) General Liability in amounts of at least
US$3,000,000.00. All insurance
amounts may be obtained by full, individual primary policy amount; a primary amount of less than
minimum requirement enhanced by a blanket excess umbrella policy; or a combination of either. Each
party shall provide the other party with a certificate of insurance upon request. The insured shall
provide the other party with at least thirty (30) days prior written notice of any material change,
cancellation or expiration of the above-required insurance.

- 6 -

 

15. Force Majeure and Related Matters. QLAB shall not be liable or responsible to Sponsor nor
be deemed to have defaulted under or breached this Agreement or any CCLS for or in respect of
errors, delays or other consequences arising from Sponsor’s failure to provide documents,
materials, information or cooperation required by QLAB in order to perform properly and timely
QLAB’s obligations hereunder or thereunder. Sponsor acknowledges that, if it materially delays or
suspends performance of the services, then the personnel and/or resources originally allocated to
the project may be re-allocated, and QLAB will not be responsible for delays due to required
re-staffing or re- allocation of resources. Any delay or hindrance in the performance of any of
the duties or obligations of either party hereto (except the payment of money owed) shall not be
considered a breach of this Agreement and the time required for performance shall be extended for a
period equal to the period of such delay, provided that such delay has been caused by or is the
result of any labor disputes, including strikes, lockouts, job actions or boycotts; inability to
procure materials or services; riots; insurrection; embargoes; war; acts of God; acts of the public
enemy; inclement weather; fires; explosions; floods or other natural disasters; or other reasons or
causes beyond the reasonable control of the party seeking to perform.

16. Notices and Deliveries. Any notice required or permitted to be given by either party
hereunder shall be in writing and shall be deemed given on the date received if delivered
personally or by nationally recognized overnight delivery service or three days after the date
postmarked if sent by registered or certified U.S. mail, return receipt requested, postage prepaid
to the following addresses:

	 	 	 	 	 	 	 	 	 
	 	 	If to QLAB:	 	 	 	Quintiles Laboratories Limited
	 	 	 	 	 	 	5500 Highlands Parkway, Suite 600
	 	 	 	 	 	 	Smyrna, Georgia 30082
	 

	 	 	 	 	 	Attn:
	 	Thomas Wollman
	 

	 	 	 	 	 	 	 	Vice President
	 
	 	 	 	 	 	 	 	 
	 	 	If to Sponsor:	 	 	 	Rx Development Resources
	 	 	 	 	 	 	3104 Cherry Palm Drive, Suite 260
	 	 	 	 	 	 	Tampa, Florida 33619
	 	 	 	 	 	 	Attn: Barry Butler

The expense and risk of loss for all deliveries, shipments, and mailings shall be born by
Sponsor. QLAB disclaims any liability for loss or damage occurring during shipment, delivery or
mailing, except to the extent that such loss or damage is caused by the negligence or intentional
misconduct of QLAB. All information transmitted by QLAB pursuant to this agreement will be sent by
the standard transmission method selected by QLAB (telephone, facsimile, mail, personal delivery
or email). Sponsor hereby consents and authorizes QLAB to send facsimiles relating to the
Services, or relating to potential future services, to any office of Sponsor or Sponsor’s
affiliates.

- 7 -

 

17. Miscellaneous.

     (a) Governing Law. This Agreement and each CCLS shall be construed, interpreted in
accordance with and enforced under the laws of the State of North Carolina, without regard to the
conflict of laws provisions thereof. If any one or more provisions of this Agreement or any CCLS
shall be found to be illegal or unenforceable in any respect, it is the intent of the parties that
such provisions be replaced, reformed or narrowed so that their original business purpose can be
accomplished to the extent permitted by law, the validity, legality and enforceability of the
remaining provisions shall not in any way be affected or impaired thereby.

     (b) Survival. The obligations of the parties contained in Sections 4, 5, 6, 8, 9 and 11 shall
survive the termination of this Agreement.

     (c) Entire Agreement; Amendments. This Agreement, together with each CCLS, contains the
entire understanding of the parties with respect to the subject matter herein, and supersedes all
previous agreements (oral and written), negotiations and discussions. The parties may modify or
amend the provisions hereof only by an instrument in writing duly executed by the parties.

     (d) Binding Agreements and Assignment. This Agreement shall be binding upon and inure to the
benefit of Sponsor and QLAB and their respective successors and permitted assigns. Neither this
Agreement nor any of either party’s rights hereunder may be assigned or otherwise transferred by
either party without the prior written consent of the other;
provided, however, QLAB may in
its sole discretion assign at any time any or all of its rights and obligations under this
Agreement to any of its corporate affiliates or may utilize any such affiliates to carry out its
obligations under this Agreement. The term “affiliate” shall mean all entities controlling,
controlled by or under common control with QLAB. The term “control” shall mean the ability to vote
fifty percent (50%) or more of the voting securities of any entity or otherwise having the ability
to influence and direct the polices and direction of an entity.

     (e) Waiver. No waiver by either party of any breach of any provision of this Agreement or any
CCLS shall constitute a waiver of any other or subsequent breach.

     (f) Headings. The descriptive headings of the sections of this Agreement are inserted for
convenience only and shall not control or affect the meaning or construction of any provision
hereof.

     (g) Incorporation by Reference. All exhibits attached hereto shall be deemed to be
incorporated herein. In case of any conflict between this Agreement and any such attachment or any
CCLS, the terms of this Agreement shall prevail over the attachment or CCLS.

     (h) Currency Exchange. The currency to be used for invoice and payment shall be the currency
stated in the Budget attached to a CCLS (the “Contracted Currency”). If a currency referenced
within the Budget is replaced by the Euro or otherwise ceases to become legal tender, the
applicable replacement currency will be substituted for such currency for the purposes of this
clause using the conversion rate established at www.oanda.com. Sponsor acknowledges that,
due to fluctuations in currency exchange rates, QLAB’s actual fees & pass-through costs may be
greater or lesser than the budgeted or estimated amounts contained in a CCLS.

- 8 -

 

     If QLAB incurs pass-through costs in a currency other than the Contracted Currency,
then Sponsor shall reimburse QLAB for QLAB’s actual costs in the Contracted Currency based on the
Oanda foreign currency exchange rate for the applicable currencies on the last business Friday of
the month.

     If a CCLS involves the performance of Services by QLAB or its affiliates in any country that
uses a currency other than the Contracted Currency, then the Budget for those Services will be
based on the local rates in the currency used by QLAB for pricing in that country, but converted
to and reflected in the Contracted Currency. If the fees for Services under a CCLS exceed
$200,000, and the conversion rate between the local currencies and the Contracted Currency has
fluctuated more than 2% plus or minus, since the budget was prepared, QLAB may calculate a foreign
currency exchange adjustment. The adjustment will be calculated every six (6) months after the
contract execution date, by comparing the foreign currency exchange rate stated in the Budget
attached to the CCLS to the Oanda average rate over the preceding six (6) months. Any resulting
decrease in costs will be immediately credited to Sponsor and any resulting increase in costs will
be invoiced to Sponsor, and shall be due for settlement without delay.

     (i) Arbitration. Any controversy or claim arising out of or relating to this Agreement or the
breach thereof shall be settled by arbitration administered by the American Arbitration
Association (“AAA”) under its Commercial Arbitration Rules, and judgment on the award rendered by
the arbitrator shall be binding and may be entered in any court having jurisdiction thereof. Such
arbitration shall be filed and conducted at the office of the AAA closest to QLAB, and shall be
conducted in English by one arbitrator mutually acceptable to the parties selected in accordance
with AAA Rules.

     (j) Data Protection. QLAB and Sponsor agree to comply with all applicable privacy laws and
regulations. If the Project will involve the collection or processing of personal data (as defined
by applicable data protection legislation) within the European Economic Area (“EEA”), then Sponsor
shall serve as the controller of such data, as defined by the European Union (“EU”) Data
Protection Directive (the “Directive”), and QLAB shall act only under the instructions of the
Sponsor in regard to personal data. If Sponsor is not based in the EEA, but personal data will be
gathered or processed in the EEA, Sponsor must appoint an EEA company to act as its local
representative for data protection purposes in order to comply with the Directive, and such
designation is attached hereto and incorporated by reference. If Sponsor does not have an
affiliate in the EEA and requests that a QLAB affiliate in the EEA serve as its local
representative, then the parties shall negotiate a fee for such representative duties and shall
enter into a Data Transfer Agreement between the parties containing the Standard Contractual
Clauses set forth by the EU Commission Decision of 15 June 2001 (Decision 2001/497/EC) before QLAB
will assume any such representative duties. If Sponsor is not based in the EEA, QLAB will not
export any personal data from the EEA unless Sponsor has appointed a local representative.

- 9 -

 

     IN WITNESS WHEREOF, this Agreement has been executed by the parties hereto through their
duly authorized officers and is effective as of the last date set forth below.

	 	 	 	 	 	 	 	 	 	 	 
	QUINTILES LABORATORIES LIMITED	 	 	 	Rx DEVELOPMENT RESOURCES	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:
/s/ Thomas Wollman

	 	 	 	By: /s/ Barry Butler	 	 
	 
	 	 	 	 
	 	 
	 

	 	Thomas Wollman	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Title:

	 	Vice President
	 	 	 	Title:
	 	Partner/CEO	 	 
	 

	 	Global Central Laboratories	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Date:

	 	9/07/05
	 	 	 	Date:
	 	9/1/05	 	 

- 10 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}]]